These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 30043421)

  • 1. FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.
    Foth M; Ismail NFB; Kung JSC; Tomlinson D; Knowles MA; Eriksson P; Sjödahl G; Salmond JM; Sansom OJ; Iwata T
    J Pathol; 2018 Nov; 246(3):331-343. PubMed ID: 30043421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
    Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
    J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
    Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
    Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
    Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
    Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.
    Tomlinson DC; Hurst CD; Knowles MA
    Oncogene; 2007 Aug; 26(40):5889-99. PubMed ID: 17384684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma.
    Shin K; Lim A; Odegaard JI; Honeycutt JD; Kawano S; Hsieh MH; Beachy PA
    Nat Cell Biol; 2014 May; 16(5):469-78. PubMed ID: 24747439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
    di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
    Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Kacew A; Sweis RF
    Front Immunol; 2020; 11():575258. PubMed ID: 33224141
    [No Abstract]   [Full Text] [Related]  

  • 12. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
    Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
    Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
    Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
    Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
    Knowles MA
    World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
    di Martino E; Alder O; Hurst CD; Knowles MA
    Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular investigation of FGFR3 gene mutation and its correlation with clinicopathological findings in Indian bladder cancer patients.
    Ahmad F; Mahal V; Verma G; Bhatia S; Das BR
    Cancer Rep (Hoboken); 2018 Oct; 1(3):e1130. PubMed ID: 32721083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.